Loading...
Loading...
ARWR| Name | Value |
|---|---|
| Revenues | 3.6M |
| Cost of Revenue | 4.3M |
| Gross Profit | -0.7M |
| Operating Expense | 140.1M |
| Operating I/L | -136.5M |
| Other Income/Expense | -2.1M |
| Interest Income | 2.8M |
| Pretax | -138.7M |
| Income Tax Expense | -3.3M |
| Net Income/Loss | -132.9M |
Arrowhead Pharmaceuticals, Inc. develops RNA interference (RNAi) therapeutic candidates for the treatment of liver diseases, hypertriglyceridemia, chronic obstructive pulmonary disorder, muscular dystrophy, gout, and COVID-19. The company's products in pipeline include ARO-AAT, ARO-APOC3, ARO-ANG3, ARO-HSD, ARO-ENaC, ARO-C3, ARO-Lung2, ARO-DUX4, ARO-XDH, ARO-COV, and ARO-HIF2. Additionally, Arrowhead is involved in the development of JNJ-3989 for chronic hepatitis B virus infection, Olpasiran to reduce apolipoprotein A production, and ARO-AMG1 for genetically validated cardiovascular targets.
